Emyria Limited is a clinical services and drug development company focused on improving patient outcomes in neuroscience and mental health via a unique business model: Emyria Care: Deliver evidence-based and emerging therapies for mental health and other unmet needs across multiple sites (Empax Centres). Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients. Emyria Data is used to improve Emyria’s distinct therapy and drug development programs. Emyria Drug Discovery: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia for a range of mental health and select neuroscience indications.
| Website | http://www.emyria.com |
| Employees | 19 (9 on RocketReach) |
| Address | 661 Newcastle St, Leederville, Western Australia 6007, AU |
| Phone | +61 1300 436 363 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+13 more
(view full list)
|
| Industry | Mental Health Care |
| Keywords | Mental Healthcare, Mental Wellness, Mental Health Services, Patient Outcomes, Brain Health, Drug Development, Evidence Based Therapies, Neuroscience Research, Neurological Disorders, Clinical Research, Clinical Trials, Precision Medicine, Drug Discovery, Pharmaceutical Research, Psychedelic Medicine, Clinical Stage, Innovative Therapies, Biotechnology, Emerging Therapies, Therapeutics |
| Competitors | Nufarm, Tilray Brands, Inc., Aurora Cannabis Inc., AFT Pharmaceuticals, PharmaCielo, Elixinol, Creso Pharma, Lexaria Bioscience, Harvest One, Reef Medical Pty Ltd +20 more (view full list) |
Looking for a particular Emyria (ASX:EMD) employee's phone or email?
Mary-Ann Rennie is the COO of Emyria (ASX:EMD).
9 people are employed at Emyria (ASX:EMD).
Emyria (ASX:EMD) is based in Leederville, Western Australia.